Cashu | Summary

DJI

-0.05%

SPX

+0.51%

IXIC

+1.02%

FTSE

+0.67%

N225

0.00%

AXJO

0.00%

HomeWatchlistNewsSignalsPicks

Stocks

0.00 (0.00%)

0.000

USD

At close at --,----

Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.

Company

About Us
Careers
Blog
News

Help & Support

Help Center
Contact Us
Pro Support

Legal

Instagram YouTube

HomeWatchlistNewsSignalsPicks

DJI

-0.05%

SPX

+0.51%

IXIC

+1.02%

FTSE

+0.67%

N225

0.00%

AXJO

0.00%

HomeWatchlistNewsSignalsPicks

Join our newsletter to keep up to date with us!

Stocks

0.00 (0.00%)

0.000

USD

At close at --,----

Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.

Company

About Us
Careers
Blog
News

Help & Support

Help Center
Contact Us
Pro Support

Legal

Instagram YouTube

Join our newsletter to keep up to date with us!

Overview

Loading chart...

Key Stats

Market Cap

35.18M

Dividend Yield

0.00%

P/E Ratio

-0.24

EPS

-2.57

Revenue

28.54M

Avg. Volume

63.32K

About

What does CASI do?

CASI Pharmaceuticals, headquartered in Beijing, focuses on developing therapeutics, including the FDA-approved EVOMELA for multiple myeloma, and has a diverse pipeline targeting hematology oncology. The company went public on August 23, 2021, and employs 176 staff.

Sector

💻 Health Care

IPO

CEO

Employees

233

Headquarters

China

Website

http://www.casipharmaceuticals.com